Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C. difficile, the fourth major biotech to take this approach toward the life-threatening bacterial ...

At the Canadian facility, between Nov. 19, 2013, and March 7, 2015, admitted patients were screened for C. diff toxin B gene with polymerase chain reaction on a rectal swab.

C. perfringens is a widespread bacterium found in the intestines of animals and humans, known for causing severe enteric diseases. It produces over 20 toxins, with the β-2 toxin (CPB2) being ...

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in ...

Finch Therapeutics announced positive topline results from a randomized controlled trial of CP101 for the prevention of recurrent Clostridioides difficile infection, according to a press release ...

A new microbiome-based treatment for Clostridioides difficile infection showed success in reducing recurrence of the infection at 8 weeks, according to preliminary results released by the ...

Three-quarters of the people who got Finch Therapeutics’ microbe-based pill for C. difficile infections appeared to be cured, the company announced Friday.

Dec. 13, 2012 -- A 2-year-old beagle named Cliff may hold the key to preventing an infection that kills thousands of Americans each year.

Rebiotix, a Ferring Company, and its parent Ferring Pharmaceuticals Group said their microbiome-based treatment candidate RBX2660 showed positive preliminary Phase III results in patients with ...